Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(2):80-81; doi:10.1093/jnci/94.2.80
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 2, 80-81, January 16, 2002
© 2002 Oxford University Press

NEWS

French Challenge to BRCA1 Patent Underlies European Discontent

Steve Benowitz

Perhaps it was inevitable. What began as a dispute between scientists at the Paris-based Institut Curie and Myriad Genetics Inc. of Salt Lake City over testing rights in France for the putative breast cancer genes BRCA1 and BRCA2 has spilled over to much of Western Europe.

The mounting opposition to the patents, which Myriad owns, now includes scores of scientists, dozens of laboratories, and several genetics societies in countries such as France, Belgium, the United Kingdom, the Netherlands, Sweden, Spain, and Germany. The French government and the European Parliament also joined the fray.

In early October, Curie and the nearby Institut Gustave-Roussy filed a formal opposition with the European Patent Office protesting the patent. At stake is the right to test for genes to determine risk for hereditary breast and ovarian . . . [Full Text of this Article]

Broader issues


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?